Navigation Links
Crystalens HD(TM) Receives FDA Approval
Date:6/30/2008

Newest Version of the Only FDA Approved Accommodating Lens Designed to

Further Improve Near Vision

ALISO VIEJO, Calif., June 30 /PRNewswire/ -- Bausch & Lomb announced today that it has received approval from the Food and Drug Administration (FDA) to market the Crystalens HD(TM) in the United States. Crystalens accommodating intraocular lens (IOL) was first approved by the FDA in November 2003. The Crystalens HD is the fourth generation of the only FDA approved accommodating lens.

The surface of the Crystalens HD has been shaped to enhance the depth of focus with a proprietary optical modification. The enhanced optic provides an increased depth of focus which is designed to improve near vision without compromising intermediate or distance vision. The HD lens does this without inducing increased undesirable dysphotopsia or night vision symptoms.

A total of 125 primary eyes were implanted with the Crystalens HD in patients who had a visually significant cataract, less than 1 diopter of corneal astigmatism, and the potential for best corrected visual acuity (BCVA) of 20/25 or better in both eyes. Of these patients, 80% reported vision at J2 or better at four (4) months.

"Extensive market research has clearly indicated that patients and surgeons alike are asking for a truly accommodating IOL as their choice of lens. With these results, where patients reported getting one more line of near vision, we are coming ever closer to meeting the desired need for an optic that does provide truly good near vision without compromising the quality of vision at intermediate or distance," said Michael Judy, Chief Marketing Officer at Bausch & Lomb Surgical.

Dr. John Hovanesian was a Principal Investigator in the FDA study. Dr. Hovanesian serves as Clinical Instructor at the Jules Stein Eye Institute, UCLA in California and is in private practice at Harvard Eye Associates in Laguna Hills, California.

"If I were a patient having cataract surgery, I would want an IOL that projects a single point of focus and also provides a broad range of distance, intermediate and near vision. The Crystalens HD is the best available lens to achieve that goal," said Dr. Hovanesian. "There is no question that the HD will be my lens of choice for presbyopia correction in patients with cataracts."

Bausch & Lomb officials said that surgeons will be instructed to continue to use the same surgical protocols for the Crystalens HD as they have used in the past. The Company has said that it will begin shipping the Crystalens HD the week of July 7th.

ABOUT CRYSTALENS HD

Crystalens HD is a product developed by Bausch & Lomb. To learn more about Crystalens HD, please visit http://www.crystalens.com. The Crystalens(R) Call Center is 1-888-393-6642.

ABOUT BAUSCH & LOMB

Bausch & Lomb is an eye health company dedicated to perfecting vision and enhancing life. Bausch & Lomb offers the world's most comprehensive portfolio of eye health products. The Company has one of the oldest, best known and most respected healthcare brands in the world. Bausch & Lomb offers a full suite of products in cataract and vitreoretinal surgery including intraocular lenses and delivery systems, phacomulsification equipment and other surgical instruments and devices. To learn more about Bausch & Lomb, visit http://www.bausch.com


'/>"/>
SOURCE Bausch & Lomb
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GSW Worldwide Named Agency of Record for BioBehavioral Diagnostics Companys MMAT/ADHD(TM) System
2. Weight Watchers Receives Adverse U.K. VAT Ruling
3. Instrumentation Laboratory Receives Performance Award from Premier for Second Consecutive Year
4. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
5. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
6. Preshaw receives Young Investigator Award
7. Childers receives research in Oral Biology Award
8. Melvin receives Salivary Research Award
9. Fischman receives Pharmacology/Therapeutics/Toxicology Research Award
10. Atchison receives Behavioral, Epidemiological and Health Services Research Award
11. Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... Wine Tasting Event in New York City, with long-time partners The Paul Foundation, ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace is ... styles with unique displacement design elements," said Christina Austin - CEO of Pixel ... from a variety of design styles that include both left aligned and right ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. Food ... Jardiance (empagliflozin) to reduce the risk of cardiovascular death ... cardiovascular disease. "Cardiovascular disease is a ... diabetes mellitus," said Jean-Marc Guettier , M.D., C.M., ... in FDA,s Center for Drug Evaluation and Research. "Availability ...
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: